TVB-2640 25 mg (US)
3V2640-CLIN-005
Phase 2 small_molecule completed
Quick answer
TVB-2640 25 mg (US) for MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) is a Phase 2 program (small_molecule) at Sagimet Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sagimet Biosciences
- Indication
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed